FindTrial
Sign In

Nivolumab or pembrolizumab

DRUG4 trials

Sponsors

Asan Medical Center, Guangdong Association of Clinical Trials, Vaxiion Therapeutics, Uppsala University

Conditions

Advanced Solid TumorAdvanced Solid Tumors Appropriate for Treatment With Either Nivolumab or PembrolizumabBiliary Tract CancerHepatocellular CarcinomaHigh-risk MelanomaLung Squamous Cell Carcinoma Stage IV

Phase 1

Phase 1 Study of Intratumoral Administration of VAX014 With Expansion in Combination With a Checkpoint Inhibitor in Subjects With Advanced Solid Tumors
RecruitingNCT05901285
Vaxiion TherapeuticsAdvanced Solid Tumor, Advanced Solid Tumors Appropriate for Treatment With Either Nivolumab or Pembrolizumab
Start: 2023-11-02End: 2027-11-01Target: 48Updated: 2026-08-24

Phase 3

Assessment of Short Immunotherapy After Radical Surgery of High-risk Malignant Melanoma
RecruitingNCT06488482
Uppsala UniversityHigh-risk Melanoma
Start: 2024-12-19End: 2033-09-01Target: 1792Updated: 2026-03-09

Unknown Phase

A Prospective Cohort Study of Patients with Hepatobiliary Cancer Treated with Immune Checkpoint Inhibitors
Active, not recruitingNCT03695952
Asan Medical CenterBiliary Tract Cancer, Hepatocellular Carcinoma
Start: 2018-07-01End: 2026-07-30Target: 100Updated: 2025-01-28
A Survival Observational Study in Patients With Advanced IIIB-IV Squamous Cell Lung Cancer Receiving PD-1 Combination With Chemotherapy
NCT04306042
Guangdong Association of Clinical TrialsLung Squamous Cell Carcinoma Stage IV
Start: 2020-03-31End: 2022-12-31Target: 1000Updated: 2020-03-12

Related Papers

Grand SLAM study protocol: a prospective randomised multicentre study of shortened versus standard duration adjuvant immune checkpoint inhibition for stage IIB-C, III and IV cutaneous melanoma
BMC Cancer2026-03-27
Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma.
2022-04-1589 citations
Molecular and Immunological Characterization of Biliary Tract Cancers: A Paradigm Shift Towards a Personalized Medicine.
2020-08-0632 citations
Efficacy and safety of pembrolizumab in patients with PD-L1 positive advanced biliary tract cancer (BTC): A prospective cohort study.
Journal of Clinical Oncology2019-05-207 citations